Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Specialized Health Care May Be Lacking under Obamacare Plans

Andrew M. Seaman  |  October 29, 2015

(Reuters Health)—Some health insurance plans sold on the Affordable Care Act‘s federal marketplace may not provide reasonable access to medical specialists, new research suggests.

Under the act, also known as Obamacare, the federal marketplace offers subsidized private health insurance to consumers in states that didn’t establish their own health insurance exchanges.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

About one in seven health insurance plans offered on the federal marketplace in 2015 did not provide access to in-network doctors for at least one medical specialty, researchers found.

“People need to be really mindful of what they’re actually getting with their plans,” said lead author Stephen Dorner, of the Harvard T.H. Chan School of Public Health in Boston.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

He and his colleagues write in JAMA that nearly 12 million Americans gained health insurance through the 2010 law’s marketplaces. By law, insurance plans are supposed to ensure “reasonable access” to providers.

For the new study, the researchers looked at 135 health insurance plans in 34 state marketplaces that were available during the 2015 open enrollment period, when people can select their plans.

Using the plans’ physician directories, they looked for in-network specialists who would be covered by insurance, including obstetricians/gynecologists, dermatologists, cardiologists, psychiatrists, oncologists, neurologists, endocrinologists, rheumatologists and pulmnologists.

Overall, in April 2015, 18 plans in nine states lacked in-network specialists for at least one specialty within a 100-mile search area, and 19 lacked specialists within a 50-mile radius.

Endocrinology, rheumatology and psychiatry were the most commonly excluded specialties.

Another seven to 14 plans had fewer than five in-network doctors in those fields.

When the researchers repeated their search in May, six of the 19 plans lacking specialists had added more providers.

The researchers also found that people enrolled in plans that lacked access to specialists had high out-of-network charges for doctors’ visits and medication. In some cases, they had to pay half or more of all costs.

“What this basically translates into is huge out-of-pocket costs for the consumers,” Dorner said.

Clare Krusing, the press secretary for America’s Health Insurance Plans, told Reuters Health by email that the new research ignored state standards for time and distance requirements.

Also, Krusing said the researchers did not account for the number of specialists operating in specific states, and didn’t acknowledge that plans have processes and programs in place to ensure patient access.

“The study’s limitations speak for themselves, and account for the fact that the report presents a misleading picture of what’s happening in the market today,” she said. “Health plans must meet state and federal network adequacy requirements that ensure patients have a wide range of providers and specialists available to them.”

Page: 1 2 | Single Page
Share: 

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Affordable Care Act (ACA)Health InsuranceObamacarespecialist

Related Articles

    What’s New in SLE: Pathogenesis & Novel Therapies

    September 8, 2022

    Thomas Dörner, MD, reviewed the current state of systemic lupus erythematosus (SLE) management, providing updates on novel therapies and insights into the pathogenesis of SLE.

    Phase 2 Trial Results for Sjögren’s Syndrome & SLE Presented in 2nd Plenary Session at ACR Convergence 2022

    November 28, 2022

    PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus. Remibrutinib in Phase 2 Sjögren’s Syndrome Trial Thomas Dörner, MD, a professor of rheumatology and clinical immunology for…

    What the Affordable Care Act Means for Rheumatology

    January 1, 2014

    Expected to flood the healthcare system with an influx of insured patients, Obamacare will likely exacerbate physician shortages, worsen capacity issues for many rheumatologists, and pressure providers to deliver a measurable quality of care, but analysts say rheumatology patients will benefit from expanded insurance coverage options

    RA Treatments Show Mixed Results

    July 13, 2017

    Highlights from the 2017 EULAR Congress MADRID—The anti-IL6 “nanobody,” vobarilizumab, produced mixed results when used with methotrexate (MTX), compared with MTX and placebo, according to results of a 24-week, double-blind Phase 2b study of patients with rheumatoid arthritis (RA), which were presented in an abstract session at the Annual European Congress of Rheumatology (EULAR). ad…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences